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ABSTRACT 
 
PGLa-AM1 (GMASKAGSVL10GKVAKVALKA20AL.NH2) was first identified in skin 
secretions of the frog Xenopus amieti (Pipidae) on the basis of its antimicrobial properties. 
PGLa-AM1 and its [A14K] and [A20K] analogues produced a concentration-dependent 
stimulation of insulin release from BRIN-BD11 rat clonal β-cells without cytotoxicity at 
concentrations up to 3 μM.  In contrast, the [A3K] was cytotoxic at concentrations ≥  30 nM.  
The potency and maximum rate of insulin release produced by the [A14K] and [A20K] peptides 
were significantly greater than produced by PGLa-AM1. [A14K]PGLa-AM1 also stimulated 
insulin release from mouse islets at concentrations ≥ 1 nM and from the 1.1B4 human-derived 
pancreatic β-cell line at concentrations > 30 pM.  PGLa-AM1 (1 µM) produced membrane 
depolarization in BRIN-BD11 cells with a small, but significant (P < 0.05), increase in 
intracellular Ca2+ concentrations but the peptide had no direct effect on KATP channels. The 
[A14K] analogue (1 µM) produced a significant increase in cAMP concentration in BRIN-BD11 
cells and down-regulation of the protein kinase A pathway by overnight incubation with 
forskolin completely abolished the insulin-releasing effects of the peptide. [A14K]PGLa-AM1 (1 
µM) protected against cytokine-induced apoptosis (p < 0.001) in BRIN-BD11 cells and 
augmented (p < 0.001) proliferation of the cells to a similar extent as GLP-1. Intraperitoneal 
administration of the [A14K] and [A20K] analogues (75nmol/kg body weight) to both lean mice 
and high fat-fed mice with insulin resistance improved glucose tolerance with a concomitant 
increase in insulin secretion.  The data provide further support for the assertion that host defense 
peptides from frogs belonging to the Pipidae family show potential for development into agents 
for the treatment of patients with Type 2 diabetes. 
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Abbreviations:  
 
CCK-8,  Cholecytokinin-8 
CPF, Caerulein precursor fragment  
EGTA,  ethylene glycol tetraacetic acid 
GLP-1,  Glucagon-like peptide 1 
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IBMX,  3-isobutyl-1-methylxanthine 
KRB, Krebs-Ringer bicarbonate buffer 
LDH, Lactate dehydrogenase   
MALDI-TOF, Matrix-assisted laser desorption/ionization-time of flight 
PGLa. Peptide glycine-leucine-amide 
PKA, Protein kinase A                                                                                                                                     
PKC,  Protein kinase C 
PMA,  phorbol 12-myristate 13-acetate 
T2DM, Type 2 diabetes mellitus 
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1. Introduction 
 
The order Anura (frogs and toads) currently contains 6660 well characterized species [1] and 
their skin secretions represent a vast reservoir of compounds with therapeutic potential for drug 
development. More than 1000 frog skin peptides have been described that possess antimicrobial 
activity with varying degrees of cytotoxicity against eukaryotic cells and it is postulated that they 
defend the host against invasion by pathogenic microorganisms in the environment [2,3]. It is 
now appreciated that these peptides are multi-functional and they may also display 
immunomodulatory, antioxidant, and chemoattractive properties [3,4]. In particular, several such 
peptides that were first identified on the basis of their antimicrobial activities have subsequently 
been found to display insulinotropic effects both in vitro using BRIN-BD11 clonal β cells and in 
vivo in both lean and insulin-resistant obese mice (reviewed in [4,5]). Consequently, these host-
defense peptides show potential for development into drugs for the treatment of patients with 
Type 2 diabetes mellitus (T2DM).  
Peptide glycine-leucine-amide (PGLa) was first identified in skin secretions of the South 
African frog Xenopus laevis [6] and subsequently othologs have been isolated from a wide range 
of species belonging to the genus Xenopus (reviewed in [7]). PGLa is best known for its broad-
spectrum antibacterial and antifungal activities and for its ability to act synergistically with 
magainin peptides [8,9].  Skin secretions of the octoploid frog Xenopus amieti contain two 
paralogous peptides related to PGLa:  PGLa-AM1 (GMASKAGSVLGKVAKVALKAAL.NH2) 
and PGLa-AM2 (GMASTAGSVLGKLAKAVAIGAL.NH2) [10]. The more cationic PGLa-
AM1 shows greater growth-inhibitory potency against Escherichia coli and Staphylococcus 
aureus [10] and the peptide is also active against several oral pathogens at concentrations that do 
not affect the viability of oral fibroblasts [11]. The possibility that PGLa-AM1 may show 
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potential for development into a drug for the treatment of T2DM is suggested by the observation 
that PGLa-AM1 stimulates the release of the potent incretin peptide glucagon-like peptide-1 
from the GLUTag murine enteroendocrine cell line at concentrations that are not toxic to the 
cells [12]. The aim of the present study was to investigate the insulinotropic actions of PGLa-
AM1 in vitro using BRIN-BD11rat clonal β-cells [13], 1.1B4 human-derived pancreatic β-cells 
[14], and dispersed isolated mouse islets and in vivo using both lean mice and mice fed a high fat 
diet to produce obesity and insulin resistance. 
One of the major disadvantages of naturally occurring peptides as therapeutic agents is 
their relatively low potency and bioavailability but these limitations may be circumvented to 
varying degrees by the design of appropriate analogues [15]. Although lacking secondary 
structure in aqueous solution, PGLa adopts an amphipathic α-helical conformation in a 
membrane-mimetic solvent (50% trifluoroethanol-water) or in the presence of negatively 
charged phosphatidylcholine /phosphatidylglycerol (3:1) vesicles [16]. Secondary structure 
prediction using the AGADIR algorithm [17] indicates that PGLa-AM1 has the propensity to 
adopt a stable α-helix from Val9 to Leu22.  Previous studies with analogues of other α-helical, 
frog skin host-defense peptides have shown that increasing cationicity by substitution of 
appropriate neutral or acidic amino acid residues by L-Lysine may produce more potent and 
effective insulin-releasing peptides [5,18-20]. Consequently, effects of increasing cationicity, by 
the substitutions by L-lysine of Ala14 and Ala20 within the α-helical domain and Lys3 outside the 
domain, on the insulin-releasing and glucose-lowering activities of the peptide were investigated. 
In addition, the mechanism of action and effects of the peptides on proliferation and apoptosis in 
BRIN-BD11 cells were determined. 
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2. Materials and Methods 
 
2.1   Peptide synthesis and purification  
 
PGLa-AM1 and its [A3K], [A14K] and [A20K] analogues were supplied in crude form 
by GL Biochem Ltd (Shanghai, China) and were purified to near homogeneity (>98% purity) by 
reversed-phase HPLC by reversed-phase HPLC on a (2.2-cm x 25-cm) Vydac 218TP1022 (C-
18) column (Grace, Deerfield, IL, USA) under the conditions previously described [11,12]. The 
identities of all peptides were confirmed by MALDI-TOF mass spectrometry using a Voyager 
DE PRO instrument (Applied Biosystems, Foster City, USA).  
 
2.2. In vitro insulin release studies using BRIN-BD11 and 1.1B4 cells 
 
The procedure for studying the effects of peptides on the release of insulin from BRIN-
BD11 rat clonal β-cells (passages 15-20)  and 1.1B4 human-derived pancreatic β-cells (passages 
25-28) has been described in detail previously [13,14]. Incubations with purified synthetic 
peptides (10-12 - 3 x 10-6 µM; n = 8) were carried out for 20 min at 37 ˚C using Krebs-Ringer 
bicarbonate (KRB) buffer supplemented with 5.6 mM glucose. After incubation, aliquots of cell 
supernatant were removed for insulin radioimmunoassay [21].  Incubations (n = 8) of BRIN-
BD11 cells were also carried out in the presence of 30 mM KCl and 30 mM KCl + 1 µM 
[A14K]PGLa-AM1. 
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2.3. Insulin-release studies using isolated mouse islets 
 
Pancreatic islets were isolated from adult, male National Institutes of Health (NIH) Swiss 
mice (Harlan Ltd, Bicester, UK) as described [22]. After 48 h of culture under the same 
conditions as used for clonal cell lines, islets were pre-incubated with 500 µL KRB containing 
0.1% bovine serum albumin, and 1.4 mM glucose (pH 7.4) for 1 h at 37 ˚C. Incubations (n = 8) 
with [A14K]PGLa-AM1(0.1 nM - 1µM), [A20K]PGLa-AM1 (0.1 nM - 1µM) and 1 µM GLP-1 
(positive control) were carried out for 1 h at 37 ˚C using KRB buffer supplemented with 16.7 
mM glucose. Aliquots of supernatant were removed for insulin radioimmunoassay and the 
insulin content of the islets following acid-ethanol extraction was determined as previously 
described [23].  
 
2.4. Cytotoxicity assay 
 
The effects of peptides upon the integrity of the plasma membrane of BRIN-BD11 cells 
was determined by measurement of the rate of release of the cytosolic enzyme lactate 
dehydrogenase (LDH) using a CytoTox 96 non-radioactive cytotoxicity assay kit (Promega, 
Southampton, UK) according to the manufacturer’s instructions as previously described [18,19].  
 
2.5. Effects of peptides on membrane depolarization and intracellular calcium ([Ca2+]i) 
The procedure for determining the effects of PGLa-AM1, [A14K]PGLa-AM1, and 
[A20K]PGLa-AM1 on membrane depolarization and intracellular Ca2+ concentrations 
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monolayers of BRIN-BD11 cells has been described previously [18]. The cells were incubated at 
37 C for 300 s with 1 µM test peptides, 5.6 mM glucose only, 5.6 mM glucose +30 mM KCl 
and 5.6 mM glucose +10 mM alanine.     
 
2.6. Patch clamp analysis 
 
Full details of the equipment and protocol for patch clamp analysis have been provided 
previously [23].  KATP currents were measured during the application of  a voltage ramp protocol 
which initially depolarized the membrane potential to  +20 mV and then progressively 
hyperpolarized to -80 mV over the course of 1 s. Ramps were applied every 5 s from a holding 
potential of 0 mV and KATP currents were selectively elicited by the application of  high K+ 
external solution containing (in mM) 130 KCl, 2.5 glucose, 10 tetraethylammonium Cl, 1.3 
MgCl2, 10 HEPES, 2 CaCl2, pH 7.4 together with 100nM penitrem A and 1μM nimodipine to 
inhibit BK and L-Type Ca2+ channels respectively. The internal (pipette) solution was K+ based 
(in mM) 130 KCl, 0.045 CaCl2, 1 MgCl2, 1 EGTA, 10 HEPES, pH 7.2). Prior to, and during 
application of 1 μM PGLa-AM1, KATP channel opening was stimulated by the addition of 200 
μM diazoxide. Current amplitudes were sampled at 10 mV intervals, normalized to membrane 
capacitance (a measure of cell surface area) and statistical analysis completed.  
 
2.7. Effects of PGLa-AM1 on cyclic AMP production 
 
The procedure for determining the effects of 1 µM [A14K]PGLa-AM1 and 10 nM GLP-1 
(positive control) on the production of cAMP in  BRIN-BD11 cells has been described 
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previously [5]. Incubations were carried out for 20 min in KRB buffer supplemented with 
5.6mM glucose and 200µM of the phophodiesterase inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX). cAMP concentrations in the cell lysate were measured using a R & D Systems 
Parameter kit (Abingdon, UK) following the manufacturer’s recommended protocol. 
 
2.8. Effects of down-regulation of the PKA and PKC pathways on insulin release 
 
It has been shown that overnight culture of BRIN-BD11 cells with the activators of the 
protein kinase A (PKA) pathway, forskolin (25µM; Sigma-Aldrich, UK) or the protein kinase C 
(PKC) pathway, phorbol 12-myristate 13-acetate (PMA; 10 nM; Sigma-Aldrich, UK)  blocks the  
stimulatory actions of compounds that activate the pathways [24]. Using a previously described 
procedure for down-regulation of these pathways [5], BRIN-BD11 cells were incubated for 20 
min in KRB buffer supplemented with 5.6mM glucose containing (A) [A14K]PGLa-AM1 
(1µM), (B) GLP-1 (10nM) and (C) CCK8 (10 nM). Control incubations with forskolin (25µM), 
PMA (10nM) and forskolin (25µM) + PMA (10 nM) were also carried out.  
 
2.9. Effects of [A14K]PGLa-AM1on cytokine-induced apoptosis in BRIN-BD11 cells 
 
For determination of the ability of [A14K]PGLa-AM1 to protect against cytokine-induced 
DNA damage, BRIN-BD11 cells were seeded at a density of 5 x 104 cells per well and  exposed 
to a cytokine mixture (200 U/ml tumor-necrosis factor-α, 20 U/ml interferon-γ, and 100 U/ml 
interleukin-1β)  in the presence or absence of [A14K]PGLa-AM1 (10-6 M) for 18 h  at 37 °C 
with GLP-1 (10-6 M) as a positive control. Cells were rinsed with 0.9% phosphate-buffered 
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saline (PBS) and fixed using 4 % paraformaldehyde. The cells were permeabilized with 0.1 M 
sodium citrate buffer, pH 6.0 at 94 °C for 20 min.  For effects on apoptosis, the cells were 
incubated with TUNEL reaction mixture (In situ Cell Death Detection Kit; Roche Diagnostics, 
Burgess Hill, UK) for 1 h at 37 °C following the manufacturer’s recommended procedure. Slides 
were viewed using a fluorescent microscope with 488 nm filter (Olympus System Microscope, 
model BX51; Southend-on-Sea, UK) and photographed by a DP70 camera adapter system. 
To determine effects on proliferation, the cells were incubated in the presence or absence 
of [A14K]PGLa-AM1 (10-6 M) for 18 h  at 37 °C with GLP-1 (10-6 M) as a positive control and 
treated as above followed by staining with rabbit anti-Ki-67 primary antibody and subsequently 
with Alexa Fluor 594 secondary antibody (Abcam. Cambridge, UK) as previously described 
[25]. Proliferation frequency was determined in a blinded fashion and expressed as % of total 
cells analysed. Approximately 150 cells per replicate were analyzed.   
 
2.10. In vivo insulin release studies 
 
All animal experiments were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and EU Directive 2010/63EU for animal experiments and approved by 
Ulster University Animal Ethics Review Committee. All necessary steps were taken to prevent 
any potential animal suffering.  The procedure for determining the effects of glucose alone (18 
mmol/kg body weight) and in combination with [A14K]PGLa-AM1 (75 nmol/kg body weight) 
or [A20K]PGLa-AM1 (75nmol/kg body weight) in overnight fasted  adult (8 week old), male, 
National Institutes of Health Swiss mice (Harlan Ltd, Bicester, UK (n =8)  has been described 
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previously [26]. Blood samples were collected before and after peptide administration at the 
different time points shown in Fig. 9.   
In a second series of experiments, mice were maintained for 3 months on a high-fat diet 
as previously described [19, 27] and displayed clear manifestations of obesity, glucose 
intolerance and insulin resistance. Overnight fasted animals (n = 8) were injected 
intraperitoneally with glucose alone (18mmol/kg body weight) or together with [A14K]PGLa-
AM1 (75nmol/kg body weight) or [A20K]PGLa-AM1 (75nmol/kg body weight). Blood samples 
were collected and analyzed as described for the lean mice. 
 
2.11. Statistical Analysis 
 
Data are compared using unpaired Student’s t test (non-parametric, with two-tailed P values and 
95% confidence interval) and one-way ANOVA with Bonferroni post-hoc test wherever 
applicable. Area under the curve (AUC) analysis is performed using the trapezoidal rule with 
baseline correction. Values are presented as mean ± SEM.  Results are considered significant if p 
< 0.05.  
 
3. Results 
 
3.1.  Effects of PGLa and analogues on insulin-release from BRIN-BD11 and 1.1B4 cells 
The glucose-responsive BRIN-BD111 cell line was generated by electrofusion of rat 
insulinoma-derived RINm5F cells with New England Deaconess Hospital rat pancreatic islet 
cells [13]. In the presence of the well-established insulin secretagogue, 10 mM alanine, the rate 
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of insulin release from BRIN-BD11 cells, increased approximately 8-fold (Fig. 1). Incubation 
with PGLa-AM1 produced a significant (P < 0.05) stimulatory response at concentrations ≥ 100 
nM with a 4-fold increase above the basal rate at 3µM. The minimum concentrations producing a 
significant increase in secretion rate for the [A14K] analog (10 pM) and for the [A14K] (30 pM) 
were significantly less and the maximum response at 3 µM were significantly greater the 
corresponding parameters for the native peptide (Fig. 1). At concentrations up to and including 3 
µM, neither PGLa-AM1 nor the [A14K] and the [A20K] peptides stimulated the release of LDH 
from the cells indicating that the integrity of the plasma membrane had not been compromised. 
In contrast, [A3K]PGLa-AM1, while potently stimulating insulin release (threshold 
concentration 3 pM), also produced an increase in the rate of release of LDH at concentrations ≥ 
30 nM (Supplementary Fig. 1). This cytotoxic analogue was not investigated further. Incubation 
of BRIN-BD11 cells with medium containing 30 mM KCl produced an increase in the rate of 
insulin release from 1.13 ± 0.14 ng/106cells/20 min  in glucose alone to 9.48 ± 0.60 
ng/106cells/20 min. This rate was significantly (P < 0.001) augmented to 12.24 ± 0.92 
ng/106cells/20 min when incubations were carried out in the presence of 30 mM KCl + 1 µM 
[A14K]PGLa-AM1. 
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Fig. 1. Comparison of the effects of (A) [A14K]-PGLa-AM1 and (B) [A20K]PGLa-AM1 with 
PGLa-AM1 on insulin release from BRIN-BD11 cells Values are mean ± SEM for n = 8. 
 *P < 0.05, **P < 0.01***P < 0.001 compared to 5.6 mM glucose alone. ΔP < 0.05, ΔΔP < 0.01, 
ΔΔΔP < 0.001 compared to PGLa-AM1.  
 
 The 1.1B4 cell line was generated by electrofusion of freshly isolated human pancreatic 
islet cells with human PANC-1 epithelial cells [14]. It displays good responsiveness to glucose 
[28] and sensitivity to cytotoxic agents [29,30] and so represents a useful surrogate for primary 
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human β-cells [31]. As shown in Fig. 2, incubation of 1.1B4 cells with [A14K]PGLa-AM1 
produced a significant (P < 0.05) increase in the rate of insulin release at concentrations ≥ 30 pM 
with an approximately 3-fold increase at 3 µM. No significant increase in the rate of LDH 
release was observed at concentrations up to and including 3 µM. The response produced by the 
GLP-1 receptor agonist exenatide-4 (10 nM) was 2-fold greater than the maximum response 
produced by 3μM [A14K]PGLa-AM1. 
 
Fig. 2. Effects of [A14K]-PGLa-AM1 on insulin release from the 1.1B4 human-derived 
pancreatic β-cell line, Values are mean ± SEM for n = 8. *P < 0.05, **P < 0.01***P < 0.001 
compared to 5.6 mM glucose alone. 
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3.2. Effects of [A14K]PGLa-AM1 and [A20K]PGLa-AM1 on insulin release from isolated 
mouse islets  
 
In the presence of 16.7 mM glucose, [A14K]PGLa-AM1 and [A20K]PGLa-AM1 
produced a concentration-dependent increase in the rate of insulin secretion from dispersed 
mouse islets (Fig. 3). A significant stimulatory effects of [A14K]PGLa-AM1 was seen at 
concentrations ≥ 1nM while [A20K]PGLa-AM1 showed a significant  stimulatory effect at 10 
nM. These effects were not accompanied by significant release of LDH from isolated islets at 
any concentration tested. The magnitude of the increase produced by 1 µM concentration of each 
peptide was not significantly different from that produced by 1 µM GLP-1. 
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Fig. 3: Effects of (A) [A14K]PGLa-AM1 and (B) [A20K]PGLa-AM1 on insulin release from 
dispersed mouse islets. Values are mean ± SEM (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001 
compared to 16.7 mM glucose alone  
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3.3. Effects of PGLa-AM1 and analogues on membrane depolarization and [Ca2+]i 
A rapid and significant (P<0.01) membrane depolarisation was observed in BRIN-BD11 
cells after treatment with PGLa-AM1 (Figs. 4A and B), [A14K] PGLa-AM1 (Fig. 4A) and 
[A20K] PGLa-AM1 (Fig. 4B. The magnitudes of the effects are compared with that produced by 
30 mM KCl in Fig. 4C.  
 
Fig. 4.  Comparison of the effects of (A) [A14K]PGLa-AM1 and (B) [A20K]PGLa-AM1 with 
PGLa-AM1 on membrane potential in BRIN-BD11 cells expressed as  relative fluorescence 
units, RFU and (C) integrated response (area under the curve). Values are mean ± SEM (n = 6).  
**P < 0.01,   ***P < 0.001 compared with 5.6 mM glucose alone. 
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The membrane depolarisation produced by the peptides was accompanied by a small but 
significant (P < 0.05) increase in intracellular calcium concentration (Figs 5A and B). The 
magnitudes of the effects are compared with that produced by 10 mM alanine in Fig. 5C. Patch 
clamp studies demonstrated that PGLa-AM1 had no significant effect on the KATP current 
activated by diazoxide in BRIN-BD11 cells (Fig. 6). 
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Fig. 5.  Comparison of the effects of (A) [A14K]PGLa-AM1 and (B) [A20K]PGLa-AM1 with 
PGLa-AM1 on intracellular calcium concentrations in BRIN-BD11 cells expressed as (A) 
relative fluorescence units, RFU and (B) integrated response (area under the curve). Values are 
mean ± SEM (n = 6). *P < 0.05, and **P < 0.01 compared with 5.6 mM glucose alone. 
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3.4. Effects of [A14K]PGLa-AM1  on intracellular concentrations of cyclic AMP   
 
In the presence of 200µM IBMX, [A14K]PGLa-AM (1 µM) produced a significant (P < 
0.01) increase in cAMP concentration in BRIN-BD11 cells compared to 5.6mM glucose 
suggesting an involvement of the PKA pathway (Fig. 7A). The magnitude of the increase was 
similar to that produced by 10 nM GLP-1.  
In a second series of experiments, the effects on [A14K]PGLa-AM1 stimulated insulin 
release of down-regulation of the PKA and PKC pathways by overnight incubation of  BRIN-
BD11 cells with forskolin and PMA respectively  were investigated.  When the activators were 
not present, the rates of insulin release produced by [A14K]PGLa-AM1, GLP-1, and CCK-8  
were significantly (P < 0.001) greater than that produced by 5.6mM glucose alone (Fig. 7B). The 
insulin stimulatory activities of [A14K]PGLa-AM1 and GLP-1, but not CCK-8, were completely 
abolished when the PKA pathway was down-regulated with 25µM forskolin.. In contrast, down-
regulation of the PKC pathway with 10 nM  PMA was without effect on the stimulatory activity 
of [A14K]PGLa-AM1 and GLP-1 but the effect of CCK-8 was abolished.  Down-regulation of 
both the PKA and PKC pathways by forskolin + PMA abolished the stimulatory responses of all 
peptides tested (Fig. 7B). 
  
22 
 
 
Fig. 7. (A) Effects of [A14K]PGLa-AM1 on cAMP production in BRIN-BD 11 cells. Values are 
mean ± SEM for n = 6. ***P<0.001 compared to 5.6 mM glucose alone. ΔΔP<0.01, ΔΔΔP<0.001 
compared to 5.6 mM glucose + IBMX. (B)  Effects of [A14K]PGLa-AM1 on insulin release 
from BRIN-BD11 cells following down regulation of the PKA and PKC pathways by overnight 
culture with 25 μM forskolin or 10 nM PMA respectively. Values are mean ± SEM for n = 8. 
***P < 0.001 compared to 5.6mM glucose, ΔΔΔP < 0.001 compared to incubation under standard 
culture conditions ϕϕP < 0.01, ϕϕϕP < 0.001 compared to incubation with forskolin , 
 ++P <0.01, +++P < 0.001, compared to respective incubation with PMA. 
23 
 
3.6.  Effects of [A14K]PGLa-AM1 on apoptosis and cell proliferation in BRIN-BD11 cells 
 
As shown in Fig. 8A, neither [A14K]PGLa-AM1 (1 µM) nor GLP-1(1 µM) alone 
affected the number of BRIN-BD11 cells exhibiting DNA damage  as measured by TUNEL 
assay. Incubation with a mixture of pro-inflamatory cytokines significantly (P < 0.001) increased 
the number of apoptotic cells by 3.7-fold. Co-incubation of the cells with [A14K]PGLa-AM1 
and the cytokine mixture significantly (P < 0.001) reduced the number of apoptotic cells by 49%. 
This value was comparable to the degree of protection (48 % reduction) provided by the same 
concentration of GLP-1. As shown in Fig. 8B, 1 µM [A14K]PGLa-AM1 significantly (P < 
0.001) stimulated proliferation of BRIN-BD11 cells by an amount (42% increase) that was 
comparable to that produced by 1 µM GLP-1 (43 % increase). 
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Fig, 8. (A) Comparison of the effects of [A14K]PGLa-AM1 (1 µM) and GLP-1 (1 µM) on 
protection against cytokine-induced apoptosis in BRIN-BD11 cells .***P < 0.001 compared to 
incubation in culture medium alone, ΔΔΔP < 0.001 compared to incubation  in cytokine-
containing medium. (B) Comparison of the effects of [A14K]PGLa-AM1 (1 µM) and GLP-1 (1 
µM) on proliferation of BRIN-BD11 cells .***P < 0.001 compared to incubation in culture 
medium alone 
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3.7.  Effects of PGLa analogues on insulin concentrations and glucose tolerance in lean and 
high-fat fed mice 
 
Administration of the peptides did not produce any apparent adverse effects in the 
animals.  Plasma glucose concentrations in lean mice receiving glucose plus [A14K]PGLa-AM1 
(75nmol/kg body weight) (Fig. 9A) or glucose plus [A20K]PGLa-AM1 (75nmol/kg body 
weight) (Fig. 9B) were not significantly different at any time point compared with animals 
receiving glucose only. However, the integrated response of plasma glucose (area under the 
curve) of the two peptides was significantly (P < 0.05) less after administration of vehicle only 
(Fig. 9C).  Plasma insulin concentrations were significantly (P < 0.05) higher at 15 min after 
glucose administration in animals receiving [A14K]PGLa-AM1 (Fig. 9D) or [A20K]PGLa-AM1 
(Fig. 9E) and the integrated response (total amount of insulin released over 60 min) was 
significantly greater  (P < 0.05) for both peptides (Fig. 9F).  
In a second series of experiments using the same protocol, plasma glucose concentrations 
in high-fat fed mice receiving intraperitoneal A14K]PGLa-AM1) or [A20K]PGLa-AM1 were 
also not significantly different at any time point compared with injection of glucose alone but the 
integrated plasma glucose response area under the curve) was significantly (P < 0.05) greater 
than after administration of both peptides (Supplementary Figure 2). Similarly, plasma insulin 
concentrations were significantly (P < 0.05) higher at 15 min after glucose administration in 
animals receiving [A14K]PGLa-AM1 and the integrated insulin responses  were significantly 
greater  for [A14K]PGLa-AM1 (P < 0.01)  and for [A20K]PGLa-AM1 (P < 0.05).   
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Fig. 9. Effects of acute administration of [A14K]PGLa-AM1 (75 nmol/kg body weight) and 
[A20K]PGLa-AM1 (75 nmol/kg body weight) on blood glucose (panels A-C) and plasma insulin 
(panels D-F) concentrations in lean  mice after intraperitoneal injection of glucose ((18 mmol/kg 
body weight). Values are mean ± SEM (n = 8). *P <  0.05, **P < 0.01 compared to glucose 
alone.  
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Discussion 
The global pandemic of T2DM has intensified the search for naturally occurring 
compounds that may be developed into therapeutic agents that maintain normoglycaemia and 
prevent or retard the development of the complications associated with the disease. Particular 
attention has been directed towards compounds that stimulate insulin release (sulphonyureas and 
incretins) [32] and long acting peptide analogues based upon the structure of the physiologically 
important incretin GLP-1 have been widely adopted in clinical practice [33]. Norepinephrine-
stimulated skin secretion of frogs belonging to the family Pipidae, comprising the genera  
Hymenochirus, Pipa, Pseudhymenochirus and Xenopus [1],  contain a diverse range of peptides 
whose primary function is probably host-defense (reviewed in [7]). Several such peptides have 
been shown to stimulate insulin release from BRIN-BD11 cells at concentrations that are 
appreciably less than those required to kill microorganisms. These include CPF-6 from Xenopus 
laevis [34], CPF-SE1 from Xenopus epitropicalis [34], hymenochirin-1B from Hymenochirus 
boettgeri [5] and pseudhymenochirin-1P and -2a from Pseudhymenochirus merlini [20]. In this 
study, PGLa-AM1 and its [A14K] and [A20K] analogues stimulate the rate of insulin release in 
vitro by BRIN-BD11 rat clonal β-cells, by the 1.1B4 human-derived pancreatic β-cell line, and 
by dispersed mouse islets at concentrations that are not toxic to the cells. Taken together, these 
results suggest that host-defense peptides from frogs belonging to the Pipidae show potential for 
development into therapeutically valuable agents for treatments of patients with T2DM. 
The ability of a cationic, α-helical peptide to permeabilize the plasma membrane of a 
mammalian cell is dependent on complex interactions between conformation, cationicity, 
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hydrophobicity, and amphipathicity.  While PGLa-AM1 and the [A14K] and the [A20K] 
analogues were not toxic to BRIN-BD11 cells at concentrations up to 3 μM, incubation with 
[A3K]PGLa-AMI in concentrations as low as 30 nM led to an increase in the rate of release of 
the cytosolic enzyme LDH indicative of loss of integrity of the plasma membrane. The changes 
in cationicity and hydrophobicity produced by the L-Ala → L-Lys substitutions are the same in 
the three analogues. Studies with a range of naturally occurring and model peptides [35-37] have 
shown that small changes in hydrophobic moment (a semi-quantitative measure of the 
amphipathicity of α-helical peptides) may produce major changes in cytolytic activity against 
microorganisms and mammalian cells, such as erythrocytes. In the absence of data derived from 
NMR measurements, one may speculate that the Ala3 → Lys substitution produces a substantial 
change in the conformation of the α-helical domain that results in a change in the degree of 
amphipathicity. 
On the basis of  previous studies, cationic insulinotropic peptides from frog skin may be 
divided into two classes. The peptides alyteserin-2a, tigerinin-1R, CPF-6, esculentin-2CHa and 
peptides of the temporin family produce cellular depolarization and increase intracellular 
calcium concentration in BRIN-BD11 cells (reviewed in [4]).  In contrast, the insulin-releasing 
actions of brevinin-2GUb, phylloseptin-L2, pseudin-2, and hymenochirin-1b do not appear to 
involve membrane depolarization or an increase in intracellular Ca2+ concentrations [4]. PGLa-
AM1, when incubated with BRIN-BD11 cells, produces membrane depolarization (Fig. 4) and a 
small but significant increase in intracellular calcium concentration (Fig. 5) but patch-clamp 
studies (Fig. 6) have shown that the insulin-releasing effects of the peptide are probably not 
mediated by a pathway which involves closure of ATP-sensitive potassium channels and opening 
of voltage-dependent calcium channels. Consistent with this proposal, the rate of insulin release 
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from BRIN-BD11 cells produced by a depolarizing stimulus (30 mM KCl) was augmented by 1 
µM PGLa-AM1 suggesting an involvement of an, as yet uncharacterized, KATP channel-
independent pathway.   
Incubation of BRIN-BD11 cells with GLP-1 stimulates cAMP production and it was 
proposed that signaling via the protein kinase A (PKA) pathway may contribute to the 
modulation of KATP independent secretory pathway triggered by the peptide [24]. PGLa-
AM1also increases intracellular cAMP concentration in BRIN-BD11 cells and down-regulation 
of PKA pathway by overnight incubation with forskolin abolishes the insulinotropic activity of 
the peptide (Fig. 7).  In contrast, down-regulation of the protein kinase C pathway by phorbol 12-
myristate 13-acetate, while attenuating the insulinotropic action of CCK-8, had no significant 
effect on the rate of insulin release produced by PGLa-AM1.  PKA activation causes a marked 
increase in L-type Ca2+ currents in cardiac myocytes [38] and it is tempting to speculate that the 
increase in cAMP concentrations produced by PGLa-AM1 increases the open probability of L-
type channels in BRIN-BD11 cells resulting in the observed depolarisation and small increase in 
[Ca2+]. 
As well as lowering blood glucose levels by stimulating insulin secretion, GLP-1 exerts 
other beneficial effects on glucose homeostasis by suppression of appetite, reduction in plasma 
glucagon concentrations, and improvement of glucose uptake in peripheral tissues. In addition, 
GLP-1 [39,40] and GLP-1 receptor agonists [41,42] stimulate β-cell proliferation and 
regeneration, and protect against β-cell damage leading to increased β-cell mass and improved β-
cell function. This study has shown that [A14K]PGLa-AM1 shows  beta-cell proliferative 
activity comparable to that  of GLP-1 when tested in BRIN-BD11 cells and is equally effective 
in  protecting the cells against  cytokine-induced apoptosis (Fig 8). A role for pro-inflammatory 
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cytokines in promoting β-cell apoptosis is well established [43,44]. β-cell mass is determined by 
the relative rates of  replenishment and death and T2DM involves a gradual decline in both the 
function and mass  of the β-cells.  Consequently, agents such as [A14K]PGLa-AM1, which not 
only stimulate insulin release but also stimulate β-cell proliferation and reduce β-cell loss, are 
attractive from a therapeutic prospective. 
 Finally, the study has shown that [A14K]PGLa-AM1 and [A20K] PGLa-AM1 display 
anti-hyperglycaemic properties in vivo when administered acutely to lean mice (Fig. 9). The 
glucose-lowering and insulin-releasing effects were significant and the magnitude of the changes 
were comparable those observed following similar administration of equimolar doses of the frog 
skin peptides phylloseptin-L2 [25], and brevinin-2GUb [45]. The high-fat fed mouse presents 
with obesity, hyperglycaemia, and insulin resistance and so is a useful model to study the 
development of metabolic syndrome and Type 2 diabetes [46,47].  The present study has 
demonstrated that [A14K]PGLa-AM1 also lowered blood glucose and enhanced insulin secretion 
in high-fat fed mice.  
In conclusion, PGLa-AM1 and its more cationic [A14K] and [A20K] analogues stimulate 
the rate of insulin release from the rat  BRIN-BD11 and human 1.1B4 established cell lines and 
are equipotent with GLP-1 in stimulating insulin release from isolated mouse islets. In addition, 
[A14K]PGLa-AM1 protects BRIN-BD11 clonal β-cells against cytokine-induced apoptosis and 
stimulates proliferation. These encouraging results warrant further studies to develop long-acting 
analogues of PGLa-AM1, for example by incorporating D-amino acids and/or  a fatty acid 
moetiy into the molecule, to stimulate the function and arrest the β-cell degeneration seen in 
patients with long-standing T2DM. 
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Supplementary Fig. 1.  Comparison of the effects of [A3K]PGLa-AM1 with PGLa-AM1 on 
(A) insulin release and (B) LDH release from BRIN-BD11 cells Values are mean ± SEM,  
  n = 8 for insulin release and n = 4 for LDH release. *P < 0.05, **P < 0.01***P<0.001 
compared to 5.6 mM glucose alone. ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 compared to PGLa-
AM1.  
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Supplementary Fig. 2. Effects of acute administration of [A14K]PGLa-AM1 (75 nmol/kg body 
weight) and [A20K]PGLa-AM1 (75 nmol/kg body weight, E-H) on blood glucose (panels A-C) 
and plasma insulin (panels D-F) concentrations in high fat fed  mice after intraperitoneal 
injection of glucose (18 mmol/kg body weight). Values are mean ± SEM (n = 8). *P < 0.05, **P 
< 0.01***P < 0.001 compared to glucose alone.  
